Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927719 · ClinicalTrials.gov registry record
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
A clinical trial of Smallpox, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- 897,227
- Enrollment target
- 4
- Study locations
NCT00927719: Completed study of Smallpox, sponsored by Emergent BioSolutions.
NCT00927719 is a study of Smallpox that has completed, run by Emergent BioSolutions. The registered enrollment target is 897,227 participants, above the 2,876-participant average among 7 other Smallpox trials with a reported enrollment target (31097% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00927719, a study of Smallpox, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- 897,227 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: * To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in temporal association with ACAM2000® vaccination. Secondary Objectives: * To evaluate the rates of cardiovascular adverse events in temporal association with ACAM2000® vaccination. * To evaluate the rates of neurological adverse events in temporal association with ACAM2000® vaccination.
Conditions Studied
Interventions
- BIOLOGICAL ACAM2000® smallpox vaccine
Study Locations (4)
Texas
- - Fort Bliss
- - Fort Hood
California
- - Twentynine Palms
Kentucky
- - Fort Campbell North
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 897,227 participants |
| Start Date | 2008-12 |
| Est. Completion | 2017-12-31 |
What the finished NCT00927719 record still lists
NCT00927719 is an observational study that tracks outcomes without assigning an intervention. Its 897,227 participants enrollment target places it among the larger protocols in the corpus, above the 2,876-participant average among 7 other Smallpox trials with a reported enrollment target (31097% higher).
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 1 intervention - of which ACAM2000® smallpox vaccine is the first listed.
NCT00927719 reports a single indexed study location in Texas, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00927719 about?
NCT00927719 is a clinical study titled "Safety Surveillance Study of ACAM2000® Vaccinia Vaccine". This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: * To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in temporal association with ACAM2000® vaccination. Secondary Objectives: ...
What is the current status of trial NCT00927719?
This trial is currently completed. The enrollment target is 897,227 participants. The study started on 2008-12. Estimated completion is 2017-12-31.
What conditions does trial NCT00927719 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT00927719?
The interventions under investigation include: ACAM2000® smallpox vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00927719?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927719 being conducted?
This trial has 4 study locations across California, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
MVA Post-Event: Administration Timing and Boost Study
COMPLETED · Phase 1
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia